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Wenlong Feng1,2, Dylan C. Dean2, Francis J. Hornicek2, Huirong Shi1* and Zhenfeng Duan1,2*Abstract
Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of
patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in
stages, with the formation of a pre-metastatic niche occurring prior to macroscopic tumor cell invasion. Exosomes
released by the primary ovarian tumor are small extracellular vesicles which prepare the distant tumor microenvironment
for accelerated metastatic invasion. They regulate intercellular communication between tumor cells and normal stroma,
cancer-associated fibroblasts, and local immune cells within the tumor microenvironment. In this review, we highlight the
emerging roles of ovarian cancer exosomes as coordinators of pre-metastatic niche formation, biomarkers amenable to
liquid biopsy, and targets of chemotherapy.
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 Ovarian cancer is the deadliest gynecological
malignancy, largely stemming from peritoneal
metastasis. Formation of the pre-metastatic niche
supports subsequent metastatic lesions.
 Ovarian cancer derived exosomes induce pre-
metastatic niche formation via immunosuppression,
angiogenesis, stromal cell remodeling, and oncogenic
reprogramming.
 Ovarian cancer derived exosomes are promising
biomarkers and therapeutic targets.
Background
Ovarian cancer is the most lethal gynecological malig-
nancy, accounting for 2.5% of all female cancers and 5%
of female cancer-related deaths [1]. In the United States,
there were approximately 22,240 new cases of ovarian
cancer diagnosed and 14,070 deaths in 2018 [2]. Ovarian
cancer patients experience high mortality rates due to
commonly being diagnosed during the late stage (III or
IV) with bowel obstruction and systemic involvement
[3]. The 5-year survival rate of ovarian cancer among© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
* Correspondence: fccshihr@zzu.edu.cn; zduan@mednet.ucla.edu
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of
Zhengzhou University, 1 Jianshe East Road, Zhengzhou 450052, Henan,
China
Full list of author information is available at the end of the articlethese late-stage III or IV cases is less than 29%, as com-
pared to 70% in early stage I cases [4]. There is, there-
fore, an urgent need to characterize the mechanisms of
ovarian cancer metastasis and associated biomarkers in
order to earlier diagnose and treat ovarian cancer pa-
tients within the stage I period.
Recent works have shown the pre-metastatic niche in
ovarian cancer to be a prevalent precondition of metas-
tasis [5]. The pre-metastatic niche is a preformed micro-
environment made possible by exosomes secreted by the
primary tumor site prior to widespread metastasis [6–8].
These exosomes optimize the environment for ovarian
cancer colonization, outgrowth, and metastasis [9, 10].
This environment is mediated through immune suppres-
sion and evasion, angiogenesis, cancer-associated fibro-
blasts (CAF), and tumor macrophages that remodel the
local stroma. Various studies have shown exosomes to
play critical roles in tumorigenesis, growth, apoptosis,
immune response, and chemotherapeutic resistance in
cancer [11–15] (Fig. 1a). However, it was not until very
recently that their roles in pre-metastatic niche estab-
lishment have been appreciated [15, 16]. Despite their
diameter of 30–100 nm, these disk-shaped membranous
vesicles contain unique signatures of proteins, lipids,
DNA, and RNA making them powerful tumorigenic
factors and diagnostic biomarkers [17]. In ovarian can-
cer, exosomes are detectable in both ascites and blood,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 a. The biogenesis of exosomes and the mechanisms involved in intercellular communication. The exosome is an intraluminal vesicle (ILV)
formed by the inward budding of the endosomal membrane during the maturation of the multivesicular endosomes (MVEs) and then secreted
after fusing with the cell surface. Uptake by recipient cells occurs via a three step processes: 1. membrane fusion with target cells; 2. endocytosis;
3. activation of surface receptors and signaling. b. Schematic diagram of the exosome. The exosome is a disk-shaped membranous vesicle with a
diameter 30–100 nm, and carries a parental cell cargo including lipids, metabolites, proteins, nucleic acids (DNA fragments, mRNA, miRNA, etc.)
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potential target of earlier targeted therapy [18–20]. In
this review, we summarize the functions of exosomes in
ovarian cancer metastasis with respect to pre-metastatic
niche formation.
Exosome biogenesis
The nature and abundance of exosomes are dictated by
their donor cell of origin — whether it be healthy tissue
or tumor [21]. Exosome biogenesis involves a set sequence
of cellular events which eventually render a carcinogenic or
physiologic subtype. The donor cells first internalize extra-
cellular ligands and products to form early endosomes.
Nascent exosomes then arise as intraluminal vesicles (ILVs)
within the lumen of these endosomes, eventually maturing
into multivesicular endosomes (MVEs) via selective inclu-
sion of proteins, nucleic acids, and lipids. Whereas some
MVEs fuse and degrade within lysosomes to provide thenecessary energy and materials for cell formation, others
are released into the extracellular environment through
Golgi recirculation or direct cell secretion [22]. The endo-
somal sorting complex required for transport (ESCRT) is a
primary driver of membrane shaping and scission, and the
first accepted mechanism of MVE and ILV formation [23].
The final exosomal cargo drives its eventual function, and
is achieved by a highly selective series of regulatory stages.
It involves endoprotein sorting and precise ESCT cleavage
of ubiquitinated proteins into ILVs via ESCT-0, −I, −II,
and -III as well as VPS4, VTA1, ALIX/PDCD6IP, and
TSG101. Lipids such as ceramide, cholesterol, and the
four-transmembrane protein superfamily including CD9,
CD63, and CD81 also mediate exosome protein sorting.
At the nucleic acid level, exosomal mRNAs are sorted into
MVEs according to the Z-zipper structure of their 3′-
UTR as well as through RNA-induced silencing com-
plexes (RISCs) [24, 25]. An ARF6–Exportin-5 axis also
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These regulatory methods demonstrate the mechanism by
which ovarian cancer exosomes obtain their distinct mo-
lecular signature from surrounding healthy tissue.Ovarian cancer-exosomes
Ovarian cancer is distinguished from other human tumors
by its preference for peritoneal cavity invasion through the
ascites, making it especially adept at involving various vis-
cera within the compartment. From the early stages on,
the ascites contains detached tumor cells, various immune
cells, mesothelial cells, and tumor associated exosomes.
These exosomes can be isolated from the ascites [27, 28]
and serum [29, 30] of patients with ovarian cancer. Im-
portantly, these exosomes contain unique protein signa-
tures specific to ovarian cancer, including membrane
proteins (Alix, TSG 101), small GTPases (Rab proteins),
annexin proteins, tetraspanins (CD9, CD82, CD63 and
CD81), heat shock proteins (Hsp90, Hsc70), antigens
(MHC I and II), Nanog and enzymes (phosphate isomer-
ase, peroxiredoxin, aldehyde reductase, fatty acid synthase)
(Fig. 1b). In addition to revealing an underlying malig-
nancy, the exosomal protein cargo functions to enhance
the progression of metastasis of ovarian tumors (Table 1).
For example, Nanog is a transcription regulator involved
in tumor cell proliferation and self-renewal of cancer stem
cells [31]. Nanog expression is significantly greater in exo-
somes sampled from the ascites of high-grade serous ovar-
ian cancer compared to benign peritoneal fluid [32].
Nanog knockout studies have shown decreased migration
and invasion of ovarian cancer cells [33].
Tumorigenic microRNAs (miRNA) have also been
identified within exosomes, where they are encapsulated
and protected from nuclease degradation. Functionally,
these intra-exosomal miRNAs regulate gene expression
of target cells both locally and systemically. Once shed,
the ovarian cancer derived exosomes horizontally trans-
port their miRNAs to tumor-associated macrophages
(TAMs), mesothelial cells, and tumor cells themselves.
They provide instructions for pre-metastatic nicheTable 1 Summary of ovarian cancer exosomal proteins involved wit
Exosomal Proteins Recipient cells
Proteomic analysis: 2230 proteins were identified N/A
ATF2, MTA1, ROCK1/2 HUVECs
GNA12, EPHA2 and COIA1 MSCs and ECs
CD44 HPMCs
RNA-binding protein LIN28 HEK293 cells
Nanog N/A
Abbreviations: ATF2 Activating transcription factor 2, MTA1 Metastasis-associated pro
Human umbilical vein endothelial cells, GNA12 Guanine nucleotide-binding pro
alpha-1 (XVIII) chain, MSCs Mesenchymal stem cells, ECs endothelial cells, HPMC
human embryonic kidneyformation and metastasis in the nascent stages of malig-
nancy (Table 2).
Exosomes cause immunosuppression within the pre-
metastatic niche
The immune system is a significant barrier to metasta-
sis. For ovarian cancer to thrive in its new environment,
it is therefore principally important for the premeta-
static niche to protect the metastatic cells from being
apoptosed upon entering the metastatic site. Exosomes
isolated from the ascites of ovarian cancer can induce a
rapid and reversible T cell arrest [17]. One recent study
found GD3, a ganglioside expressed on the surface of
exosomes isolated from ascites, to arrest T cells via act-
ing on their T-cell receptor (TCR) [46]. Ovarian cancer
associated exosomes can also induce the production of
IL-6 within monocytes through toll-like receptor (TLR)
activation. IL-6 then activates the signal transducer and
activator of transcription 3 (STAT3) pathway in immune
cells, stromal cells, and tumor cells, which supports
overall immune escape of cancer cells [47] (Fig. 2a).
With the aim of revealing the direct effect of exosomes
on immune cells, various works have cocultured exo-
somes from the ascites of ovarian cancer patients with
dendritic cells, hematopoietic stem cells, and peripheral
blood lymphocytes. One such study showed exosomes to
cause immunosuppression by inducing apoptosis of
hematopoietic stem cells, dendritic cells, and peripheral
blood lymphocytes [27] (Fig. 2a). In another study, nor-
mal peripheral blood lymphocytes were cocultured with
exosomes from ovarian cancer ascites or peritoneal
washings of patients with benign ovarian cysts with fol-
low up gene expression analysis of the lymphocytes.
They found overexpression of 26 immunosuppressive
genes in the malignant ascites cocultured group com-
pared to the benign ovarian cyst group. These findings
support the role of exosomes in dampening peripheral
immunity through direct interaction with leukocytes,
allowing for unmitigated tumor invasion [48].
Both the adaptive immune response, including CD4+
and CD8+ T cells, as well as innate immune cells suchh metastasis
Role/Mechanism Reference
Tumorigenesis and metastasis [34]
Angiogenesis [35]
Promote MSC and EC migration for metastasis [36]
Tumor cell invasion. [37]
Increase HEK293 cell invasion and migration [38]
Tumor cell proliferation and invasion [32, 33]
tein 1, ROCK Rho-Associated, Coiled-Coil Containing Protein Kinase, HUVECs
tein subunit alpha-12, EPHA2 ephrin type-A receptor 2, COIA1 Collagen
s Human peritoneal mesothelial cells, LIN28 Lin-28 homolog A, HEK293
Table 2 Summary of ovarian cancer exosomal miRNAs involved with metastasis
Exosomal miRNAs Recipient cells Role/Mechanism Reference
miR-940, miR-222-3p,miR-21–3p,
miR-125 b-5p, miR-181 d-5p
TAMs M2 phenotype polarization, EOC proliferation and migration [39–41]
miRNA 21 and 29a ES2 OC cellsLP9 mesothelial cells Mesothelial cell clearance [42]
miR-99a-5p HPMC Cell invasion through fibronectin and vitronectin upregulation [43]
MMP1 mRNAs MeT-5A and HPMC Destruction of peritoneal mesothelium barrier [44]
let-7a-f and miR-200a-c N/A Correlates with ovarian cancer invasiveness [45]
Abbreviations: TAMs Tumor-associated macrophages, HPMC Human peritoneal mesothelial cells, OC ovarian cancer, EOC Epithelial ovarian cancer, MMP
Matrix metallopeptidase
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strongly recruited to the metastatic site. These immune
cells are potent physiologic defenses against tumor pro-
gression [49]. A growing body of evidence suggests exo-
somes derived from ovarian cancer cells can silenceFig. 2 Impact of ovarian cancer-exosomes on target cells during pre-metas
dendritic cells, increase secretion of IL-6, and inhibit function of T cells and
MTA1, sE-cad, and CD147, which acts on human vein endothelial cells, indu
exosomes convert fibroblasts to CAFs. d. Ovarian cancer-exosomes deliver
regulating the suppressor of cytokine signaling (SOCS)4/5/ STAT3 pathway
induced by ovarian cancer-exosomes, clears the mesothelial cell barrier of
ATF2 Activating transcription factor 2, MTA1 Metastasis-associated protein 1
Signal transducer and activator of transcription 3, PMC Peritoneal mesothelthese immune cells in the tumor microenvironment and
are critical in pre-metastatic niche formation [50–52]. In
addition to reprogramming the immune cell gene pro-
file, ovarian cancer cells release Fas ligand (FasL)-carry-
ing exosomes which downregulate the expression of thetatic niche formation. a. Ovarian cancer-exosomes induce apoptosis of
NK cells. b. Ovarian cancer-exosomes with their cargo, such as ATF2,
cing angiogenesis and vascular permeability. c. Ovarian cancer-
miRNAs to macrophages and elicit M2 macrophage polarization by
in macrophages. e. Phenotypic conversion and apoptosis of PMCs,
the peritoneum and omentum. OC ovarian cancer, NK natural killer,
, sE-cad soluble E-cadherin, SOCS Suppress cytokine signaling, STAT3
ial cell, CAF cancer-associated fibroblast
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apoptosis [53, 54]. At the cellular level, lysophosphatidic
acid elevates the expression of FasL on the surface of
ovarian cancer cells, thus prompting the release of FasL-
carrying exosomes [55]. In addition, ovarian cancer exo-
somes carry phosphatidylserine, which inhibits T-cell ac-
tivation by blocking intracellular signaling cascades [56].
NK cells are prominent innate immune effector cells
that recognize and kill tumor cells directly. The NKG2D
receptor-ligand is a crucial activating cytotoxic receptor
of NK cells and a target of ovarian cancer exosome
downregulation. Inhibition of NKG2D circumvents NK
cell cytotoxicity, allowing for immune evasion of tumor
cells and a robust pre-metastatic niche [57] (Table 3)
(Fig. 2a).
Exosomes promote angiogenesis in the pre-metastatic niche
To ensure adequate blood supply, VEGFR1+ hematopoietic
progenitor cells initiate angiogenesis within the pre-
metastatic niche [9]. Additionally, local endothelial pro-
genitor cells promote angiogenesis via VEGF signaling
[52]. Aside from blood vessel growth, the proangiogenic
microenvironment increases vascular permeability towards
the pre-metastatic niche for multiple cell types, including
VEGFR1+ hematopoietic progenitor cells, immune cells,
stromal cells, and the homing of tumor cells [52]. This
antecedent angiogenesis makes the pre-metastatic niche
capable of meeting the nutrient requirements for subse-
quent rapid metastatic growth. Ovarian cancer exosomes
have recently gained notoriety for promoting angiogenesis
(Fig. 2b). One such study demonstrated their ability to en-
hance viability and migration of human umbilical veinTable 3 Roles of ovarian cancer exosomes in pre-metastatic niche f
Exosome Function Origin of exosomes Recipient cells Effect
Immunosuppression Ascites of OC patients T cells Arrest T cells
Ascites of OC patients Monocytes Cytokine pro
Ascites of OC patients PBMCs and DCs Apoptosis
Ascites of OC patients T cells Apoptosis
OC cells T cells Counterattac
Ovarian tumor tissues T cells T cell inhibit
EOC cells and ascites NK cells Cytotoxicity
Angiogenesis OC cells HUVECs Affect VEGF
OC cells HUVECs CD147 stimu
OC cells HUVECs Activate β-ca
Stroma remodeling OC cells ADSCs Transition AD
OC cells Macrophages Macrophage
Abbreviations: OC ovarian cancer, GD 3 ganglioside 3, TCR T-cell receptor, TLR Toll-lik
ligand, LPA Lysophosphatidic acid, PS phosphatidylserine, EOC Epithelial ovarian can
vein endothelial cells, sE-cad soluble E-cadherin, ADSCs adipose tissue-derived mese
derived factor 1, PI3K Phosphoinositide 3-kinases, AKT Protein kinase B, SOCS Supprendothelial cells. At the molecular level, proteomics have
revealed activating transcription factor 2 (ATF2) and
metastasis-associated protein 1 (MTA1) housed within
ovarian cancer exosomes to upregulate angiogenesis [58].
CD147 is a tumorigenic membrane-bound molecule
expressed in cancer cells which regulates matrix metallo-
proteinase expression in peritumoral stromal cells. CD147-
positive exosomes released by ovarian tumors promote
angiogenesis in human umbilical vein endothelial cells as
well [59]. In a uniquely VEGF-independent manner, soluble
E-cadherin (sE-cad) harboring exosomes are present within
the ascites of ovarian cancer patients and are robust activa-
tors of angiogenesis. Mechanistically, sE-cad-positive exo-
somes bind with VE-cadherin on endothelial cells,
prompting a signaling cascade that ultimately activates β-
catenin and NF-κB; this stimulates endothelial cell migra-
tion and overall vascular permeability [60]. Despite their
small size, a growing body of research is supporting the role
of ovarian cancer derived exosomes in cultivating an angio-
genic tumor niche for widespread peritoneal metastasis.
Exosomes in stromal remodeling
The survival of cancer cells that metastasize from pri-
mary tumors to secondary sites depends upon the
stroma microenvironment. Tumor derived exosomes
assist in this process by educating and remodeling stro-
mal cells in the metastatic site to support tumor cell
viability and metastatic dissemination. Functionally,
they reprogram stromal cells in the pre-metastatic niche in-
cluding cancer-associated fibroblasts (CAFs) and pericytes.
Exosomes also interact with tumor-associated macrophages
(TAM) in the metastatic microenvironment, which areormation
Potential targets Ref.
GD3, TCR [46]
duction TLR signaling pathways [47]
FasL [27]
FasL [54]
k against activated T cells LPA and FasL [55]
ion Depletion or blockade of PS [56]
inhibition NKG2D [57]
or HIF-1α ATF2 and MTA1 [58]
lates VEGF expression CD147 [59]
tenin and NF-κB signaling sE-cad [60]
SCs to CAFs α-SMA, SDF-1, TGF-β SMAD2 and
PI3K/AKT pathway
[67]
M2 polarization miR-21–3p, miR-125b-5p, and
miR-181d-5p SOCS4/5/ STAT3 pathway
[41]
e receptor, PBMCs peripheral blood lymphocytes, DCs dendritic cells, FasL Fas
cer, NK natural killer, HIF Hypoxia-inducible factor, HUVECs Human umbilical
nchymal stem cells, α-SMA alpha-smooth muscle actin, SDF-1 stromal cell-
ess cytokine signaling, STAT3 Signal transducer and activator of transcription 3
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overall metastasis.
Exosomes convert fibroblasts to CAFs
CAFs are unique, reprogrammed stromal cells with roles
in cancer initiation, extracellular matrix remodeling, pro-
gression, pre-metastatic niche formation, and metastasis
[61]. They secrete a tumorigenic cytokine milieu of
TGF-β, stromal cell-derived factor-1α (SDF-1α), S100A4,
fibronectin, and matrix metalloproteinases in the local
stromal cell microenvironment [62, 63]. While these sig-
naling molecules have unique and specific processes in
forming the tumor microenvironment, they all contrib-
ute to stromal remodeling within the pre-metastatic
niche [62, 64]. In a study where the miRNA profile
between normal fibroblasts and ovarian tumor-adjacent
fibroblasts were compared, ovarian tumor-adjacent fi-
broblasts consistently showed miR-31 and miR-214
downregulation with miR-155 upregulation. These re-
searchers demonstrated the significance of this miRNA
signature by transfecting miR-31 and miR-214 mimics
or miR-155 inhibitors into normal fibroblasts, which
caused them to convert to CAFs [65]. This showed ovar-
ian cancer derived exosomes alone are sufficient to in-
duce the phenotypic and functional changes in normal
stromal fibroblasts to pathogenic CAFs [66] (Fig. 2c).
Similar work has supported the role of exosomes in
transitioning normal stroma to CAFs. Ovarian cancer is
able to transition adipose derived mesenchymal stem
cells to CAFs by overexpressing alpha-smooth muscle
actin (α-SMA), SDF-1 and TGF-β [67]. Reprogramming
of normal stroma to cancerous stroma can therefore be
mediated by cytokine signaling from exosomes prior to
secondary metastatic growth.
Exosomes induce macrophage polarization
Macrophages are multifunctional antigen presenting
cells classically categorized into two polarized pheno-
types: pro-inflammatory (M1) and anti-inflammatory
(M2) [68]. Tumor associate-macrophages (TAMs) are of
the M2 subtype and permeate malignant tissues [69].
Within the tumor microenvironment, TAMs secrete IL-
4, IL-5, and IL-6, which promote angiogenesis, matrix
remodeling, and immune system suppression [70]. They
also contribute to the pre-metastatic niche by secreting
TGF-β, SDF-1, and VEGF via the STAT3 signaling cas-
cade [71]. In ovarian cancer, hypoxia-inducible factors
(HIFs) induce the release of exosomes enriched with
various miRNAs, including miR-21–3p, miR-125 b-5p,
and miR-181 d-5p. When these exosomes are phagocy-
tosed by undifferentiated macrophages, they undergo
M2 polarization via the suppressor of cytokine signaling
(SOCS)4/5/ STAT3 pathway [41] (Fig. 2d). One recent
study showed ovarian cancer cells co-cultured withmacrophages are only capable of transferring their onco-
genic miR-1246 via exosomes to M2 macrophages and
not to M1 macrophages. As a follow up, a combination
miR-1246 inhibitor and chemotherapy regimen signifi-
cantly reduced tumor burden in vivo [72]. These emerging
works have supported the role of directing the M2 subtype
at multiple stages of tumorigenesis and pre-metastatic
niche formation.
Exosome-educated cells in the pre-metastatic niche
promote metastasis
Ovarian cancer exosomes directly promote circulating
tumor cell homing, colonization, and outgrowth within
the premetastatic niche while suppressing the host anti-
tumor immune response. They also enable tumor cell
proliferation and invasion by encouraging host cell
transformation to TAM and CAF phenotypes (Table 3).
Experimental evidence has shown exosome-educated
TAMs to enhance ovarian cancer proliferation and mi-
gration in vitro and with in vivo mouse models [41].
This occurs as a result of the cytokine profile of TAMs,
whereby they secrete large amounts of EGF which acti-
vate EGFR in peripheral ovarian cancer cells. This EGF/
EGFR signaling cascade upregulates vascular endothelial
growth factor-C (VEGF-C), which in turn upregulates
integrin and intercellular adhesion molecule (ICAM-1).
This induces proliferation, migration, adhesion, spheroid
formation, and peritoneal implantation of ovarian cancer
cells [73] (Fig. 3b). In the pre-metastatic niche, the
tumor derived exosomes convert local fibroblasts into
CAFs, which support tumorigenesis through their own
exosome secretion. When ovarian cancer cells ingest
TGFβ1-enriched CAF-exosomes, they upregulate TGFβ1
expression and become more adept at migration and in-
vasion via a SMAD signaling cascade [74]. Aside from
this function, CAFs also enhance basement membrane
permeability allowing tumor cells to better invade the
local uninvolved stroma [75].
There is a unique interplay between chemotherapeutic
and exosome function. Intriguingly, it was recently shown
that breast cancer exosomes have enhanced pre-metastatic
niche forming ability in the lung after a chemotherapy
application [76]. In another study, researchers showed
the first-line chemotherapeutic cisplatin to increase IL-
6-producing myofibroblastic CAFs in ovarian cancer
patients by activating the NFκB signaling pathway [77].
Furthermore, they demonstrated pretreatment with the
well-known diabetes drug metformin arrested stromal
NFκB/IL6 activation and lessened the chemoresistance
response in ovarian cancer cells [77]. Metastatic and
drug-resistant, recurrent ovarian cancer produces sig-
nificantly higher IL-6 compared to matched primary tu-
mors. When elevated, IL-6 within the ascites of ovarian
cancer patients correlates with poor outcomes [78–81].
Fig. 3 Two main methods of ovarian cancer metastasis within the peritoneal cavity, direct implantation and hematogenous spread. a Distribution
of ovarian cancer nests in the peritoneal cavity. b Mechanisms of ovarian cancer-exosome establishment of the pre-metastatic niche before
metastasis. c After the formation of pre-metastatic niche, tumor cells home to the metastatic site then colonize and support vessel budding. OC:
ovarian cancer; NK: natural killer; HUVECs: Human umbilical vein endothelial cells; TAM: tumor-associated macrophages; PMC: Peritoneal
mesothelial cell; CAF: cancer-associated fibroblasts.
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tagonists, classically used to treat rheumatoid arthritis, for
their potential anti-cancer effects [82].
Exosomes breach the barriers to tumor invasion within
the pre-metastatic niche
Approximately 70% of ovarian cancer patients have peri-
toneal metastasis at the time of surgery [83]. Typically,
nests of tumor cells involve the peritoneum, omentum,
mesentery, diaphragm, and surface of abdominopelvic vis-
cera (Fig. 3a). These niduses of metastasis result from trans-
port within the ascites; however, cases of hematogenous
metastasis to the omentum also occur [84] (Fig. 3a). Histo-
logically, both the omentum and peritoneum are loose
collagen networks with vascularized connective tissue, scat-
tered fibroblasts, adipocytes, and macrophages. They are
covered by a single layer of microvilli-rich mesothelial cells
and a thin basement membrane [85](Fig. 3b), which thecirculating ovarian cancer cells must breach. The method
of metastatic transport determines the barriers to invasion.
In the hematogenous pathway, tumor cells penetrate sur-
face endothelium, and, in the ascites pathway, they infiltrate
the mesothelium (Fig. 3c).
Ovarian cancer exosomes advance angiogenesis by
inducing vascular endothelial cell migration, which facil-
itates tumor cell homing to the pre-metastatic niche
[58–60]. The notable absence of mesothelium in peri-
toneal viscera with metastatic growth suggests these cells
are cleared during tumorigenesis, and possibly prior to
large-scale metastatic invasion [86–88]. Mechanistically,
ovarian cancer cells release exosomes with specific miR-
NAs (e.g miR-21 and miR-29a) into the ascites that
remodel the mesothelial cell layer for enhanced periton-
eal penetration [42] (Fig. 2e). Serum miR-99a-5p is sig-
nificantly elevated in ovarian cancer patients and
promotes cell invasion by affecting human peritoneal
Feng et al. Molecular Cancer          (2019) 18:124 Page 8 of 11mesothelial cells (HPMCs) via fibronectin and vitronec-
tin upregulation [43]. CD44 is overexpressed in the peri-
toneal mesothelial cells of ovarian cancer patients with
omental metastasis. This occurs via an exosome condi-
tioned pathway, whereby ovarian cancer exosomes trans-
fer CD44 to peritoneal mesothelium causing its physical
barrier to be cleared [37]. MMP1 expression is a nega-
tive factor of ovarian cancer prognosis. The mRNA of
these proteases are horizontally transferred from ovarian
cancer exosomes to peritoneal mesothelium, causing
apoptosis of the peritoneal mesothelium through self-
destruction [44].
Exosomes as pre-metastatic niche biomarkers and
therapeutic applications
Early detection of the pre-metastatic niche prior to
metastasis remains an important goal within the field of
gynecologic oncology, especially given the substantially
worse outcomes associated with late stage diagnosis.
Therefore, new techniques have sought to detect hyper-
permeable, hypoxic, and inflammatory areas in addition
to areas with altered extracellular matrix profiles charac-
teristic of the metastatic niche. However, many of these
techniques have low accuracy and are not yet suitable
for clinical application [89–91]. Exosomes possess sev-
eral unique advantages as biomarkers of pre-metastatic
niche formation, as they are extremely stable, abundant,
and tumor-specific. They are, therefore, promising bio-
markers within the blood or ascites that warrant serious
investigation in this deadly cancer, especially given their
successes in other cancers [92]. For example, exosomes
derived from pancreatic tumors bearing migration inhibi-
tory factor (MIF) are selectively ingested by Kupffer cells
within the liver, and therefore serve as important initiating
factors in hepatic pre-metastatic niche formation [93].
Similarly, exosomal levels of the melanoma-specific pro-
tein tyrosinase-related protein 2 (TYRP2) has gained inter-
est as a predictor of metastasis in melanoma [94].
Liquid biopsy is a technique where circulating tumor
cells, cell-free nucleic acids, and tumor-derived exosomes
can be analyzed from body fluids such as blood or ascites.
The first exosome-based cancer diagnostic product was in-
troduced to market within the United States on January 21,
2016 [95]. This technique is especially applicable to ovarian
cancer diagnostics, as exosomes can be readily detected
from ascites in a relatively non-invasive manner [96]. The
most advanced biosensors in liquid biopsy detect cancer-
derived exosomes via highly specific target selection, bio-
logic antigen sensing, and signal transduction techniques
[97]. As to target selection, levels of exosomal miR-200b
and miR-200c are associated with poor outcomes in ovarian
cancer and significantly correlate with the ovarian tumor
marker CA-125 [98]. Cancer-related antigens are promin-
ent on the surface of exosomes and amenable to highlysensitive cancer cell detection. Examples include exosomes
enriched with VEGF-A, semaphorin-3A, and TGF-beta in
glioma (GBMs), HIF1-α in nasopharyngeal carcinoma, and
MT1 MMP in fibrosarcoma and melanoma [22]. These
proteins associated with exosomes are unique to their
cancer of origin, and therefore promising targets of li-
quid biopsy detection especially for patients with an
unknown cancer subtype. To this effect, various ma-
lignancies have been studied including melanoma,
nasopharyngeal carcinoma, breast cancer, colorectal
cancer, and ovarian cancer [97]. Very recently, a
microfluidic chip-based liquid biopsy was able to iso-
late exosomes with detailed protein and signaling
pathway profiles in ovarian cancer [99].
Therapeutic exosome-based strategies are also emer-
ging, and function by exploiting the homing effect of
exosomes on primary cancer cells [100]. A pre-
metastatic niche mimic was generated by embedding
ovarian cancer-exosomes into engineered biomaterials
and implanted within the abdominal cavity of a mur-
ine model. This artificial pre-metastatic niche effect-
ively recruited and trapped free ovarian cancer cells
from the ascites, thus preventing these cells from homing
towards normal pelvic viscera. Survival was substantially in-
creased [101]. Another emerging technology utilizes cell-
targeting aptamer-modified extracellular vesicles with exo-
somes embedded in black phosphorus. While the aptamer
directs the bioinspired extracellular vesicles towards targeted
cells, the black phosphorous derived inorganic phosphate fa-
cilitates cell biomineralization [102]. This targeted technol-
ogy has potential for elimination of the pre-metastatic niche
and is a novel area of future chemotherapeutic research.
Tumor-derived exosomes undergo homing to pre-
ferred organ and cell-specific sites when preparing the
pre-metastatic niche. Exosomal proteomics have re-
vealed expression patterns of integrins to play a major
role in this process. While the exosomal integrins
α6β4 and α6β1 promote lung metastasis, αvβ5 is linked
to liver metastasis. Therapeutically, targeting integrins
α6β4 and αvβ5 reduces exosome uptake and lung and
liver metastasis, respectively [103]. These exosomal
integrins are an additional predictor of pre-metastatic
niche formation in liquid biopsy, and especially valu-
able for cancers with high rates of metastasis. Overall,
because different cancers exhibit distinct mechanisms
and exosome profiles in their respective pre-
metastatic niches [93, 103, 104], it is likely that tumor
specific biomarkers and therapeutic strategies will
have acceptable specificity. In addition, given the pre-
metastatic biomarker profile housed within ovarian
cancer exosomes and their roles in pre-metastatic
niche formation, recent advances in liquid biopsy
diagnostics have made exosomes a promising new
area of early screening and detection (Table 3).
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Ovarian cancer exosomes promote pre-metastatic niche
formation via immunosuppression, angiogenesis, stromal
cell remodeling, and oncogenic reprogramming (Fig. 2).
Since the pre-metastatic niche gained critical attention
in 2005 [9], significant progress has been made in under-
standing the contribution of exosomes in conditioning
the pre-metastatic niche for subsequent rapid metastatic
growth. However, the roles of cell-shed exosomes have
only recently been appreciated for their substantial ef-
fects on shaping the tumor microenvironment. In the
preclinical work to date, exosomes in animal studies
have been isolated and purified in vitro. Emerging technolo-
gies such as liquid biopsy will likely further characterize
their tumorigenic effects in vivo, and may help to fully re-
veal the clinical significance of these pro-metastatic factors
in ovarian cancer.
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